Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE101 in IgA Nephropathy
NCT07902817Phase 3Recruiting
- Sponsor
- Jade Biosciences, Inc.
- Start
- Dec 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 3 trial of JADE101 in IgA nephropathy (IgAN), sponsored by Jade Biosciences, Inc.. Planned start Dec 2026; status: recruiting.
02
Drugs
JADE101
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07902817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902817.